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Earlier reports have demonstrated that exogenous somatostatin suppressed the enhanced plasma renin activity (PRA) induced by furosemide stimulation (Rosenthal et al., 1976 , Gomez-Pan et al., 1976 , beta-adrener gic stimulation (Rosenthal et al., 1977) and pentobarbital anesthesia (Izumi et al., 1979) and decreased the PRA in the basal condition in high renin essential hypertension (EH) (Rosenthal et al., 1978) . The PRA inhibiting mechanism of this peptide was considered to be similar to that of a betareceptor-blocking agent. Rosenthal et al. (1977) (27.2•}2.2) close to the basal value 15 min after discontinuation of the infusion. Figure 2 summarizes the effects of the somatostatin infusion on MBP (upper graph) and PRA (lower graph) in all patients with EH. The MBP during somatostatin infusion remained essentially unchanged, while a small but statistically significant decrease in PRA was observed 30 and 60 min after initiation of the infusion. The basal level of PRA at 0 min was 2.6•}0.6 ng/ml/h (mean•} SE) and the lower levels of PRA at 30 and 60 min were 2.0•}0.4 and 1.9 •}0.4, respectively.
The data for MBP and PRA in hypertensive patients were divided into 3 groups according to renin status, and analyzed. As shown in Fig. 3 blood pressure and a feeling oppression of the chest. The mechanism whereby a high concentration of the circulating peptide following acute administration induced untoward clinical symptoms remains unexplained. The suppressing effect of somatostatin on PRA is probably not dose-dependent, since we have previously shown that intrarenal arterial infusion of the peptide was increasingly effective in lowering the PRA in the renal vein when the administered dose was decreasing (Izumi et al., 1979) . Secondly, to classify EH patients according to their renin levels, we followed the criteria of Honda et al., in which the division was based on both the basal and furosemide-stimulated condition. The detailed criteria undoubtedly differ from those used by Rosenthal et al. Thirdly, the genesis of EH is considered to show some disparity between Japan and Europe. (Izumi et al., 1979) . Rosenthal et al. assumed that somatostatin could be characterized as a beta-blocker and action as an alpha-blocker was discounted by Schmitt et al. (1979) . It was reported by Niftilan et al. (1978) that renin release in vitro was enhanced by a betastimulator.
A relationship between renin release and cyclic AMP had been previously proposed (Hamet et al. 1974) . On the basis of these views, it can be inferred that parallel decreases in renin release and cyclic AMP due to somatostatin action could occur in in vitro experiments.
Determinations of the plasma levels of GH and cyclic AMP were carried out to assess the efficiency of exogenous somatostatin in vivo. The GH levels were suppressed, as observed in many previous studies (Brazeau et al., 1973; Mortimer et al., 1974; Brzeau et al., 1974) . The inhibition of plasma cyclic AMP levels in the present study is probably in agreement with the previous report of Herthelendy et al. (1977) in which urinary cyclic AMP excretion in the rat was inhibited by somatostatin administration.
Although some evidence suppests a relationship between control of renin release and cyclic AMP (Hamet et al. 1974) , the significant decrease in plasma level of cyclic AMP observed in the present study could not verify this relationship between renin release and cyclic AMP.
Rasmussen (1970) stated in his review that cyclic AMP has been implicated as an intermediate in the action mechanism of many hormones at the cell level. The observed reduction in this nucleotide in the present study might therefore have resulted from the effects of somatostatin on several organs in vivo. In any case, the reduction of GH and cyclic AMP clearly demonstrated the activity of exogenous somatostatin in our study.
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